Key Details
Price
$9.70Annual ROE
-67.23%Beta
0.77Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 28, 2020Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in the following December investor events.
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra's specialty pharmacy for dispense
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Nichol Ochsner - VP, IR & Corporate Communications Neil McFarlane - President & CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer & EVP, Business Development Conference Call Participants Jason Butler - JMP Securities Louise Chen - Cantor Fitzgerald Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Sumant Kulkarni - Canaccord Genuity Oren Livnat - H.C. Wainwright Operator Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.40 per share a year ago.
Data show that the NPCCSS swallow score reflects the patient's level of dysfunction Study indicates that a change in score reflects actual improvement or worsening in a patient's swallowing function CELEBRATION, Fla., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Elizabeth Berry-Kravis, M.D.
CELEBRATION, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference Virtual on Wednesday, Nov. 13, 2024, at 4 p.m. ET. Additionally, management will be available for one-on-one meetings with registered attendees.
CELEBRATION, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC on Thursday, October 17, 2024 at 2 p.m. ET.
The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a commercial-stage rare disease therapeutics company, today announced that Rene Braeckman, Ph.D.
FAQ
- What is the primary business of Zevra Therapeutics?
- What is the ticker symbol for Zevra Therapeutics?
- Does Zevra Therapeutics pay dividends?
- What sector is Zevra Therapeutics in?
- What industry is Zevra Therapeutics in?
- What country is Zevra Therapeutics based in?
- When did Zevra Therapeutics go public?
- Is Zevra Therapeutics in the S&P 500?
- Is Zevra Therapeutics in the NASDAQ 100?
- Is Zevra Therapeutics in the Dow Jones?
- When was Zevra Therapeutics's last earnings report?
- When does Zevra Therapeutics report earnings?
- Should I buy Zevra Therapeutics stock now?